Structural basis for continued antibody evasion by the SARS-CoV-2 receptor binding domainKatherine Nabel Smith, Jonathan Abraham, Sarah A. Clark et al.|Science|2022Cited by 88
Longitudinal SARS-CoV-2 Nucleocapsid Antibody Kinetics, Seroreversion, and Implications for Seroepidemiologic StudiesMichael A. Loesche, Eric J. Nilles, Elizabeth W. Karlson et al.|Emerging infectious diseases|2022Cited by 57
Severe Acute Respiratory Syndrome Coronavirus 2 Messenger RNA Vaccines in Allogeneic Hematopoietic Stem Cell Transplant Recipients: Immunogenicity and ReactogenicityAmy C Sherman, Lindsey R. Baden, Robert J. Soiffer et al.|Clinical Infectious Diseases|2021Cited by 24
Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Immunogenicity among Chimeric Antigen Receptor T Cell Therapy RecipientsMuneerah M Aleissa, Amy C Sherman, Sarah P. Hammond et al.|Transplantation and Cellular Therapy|2023Cited by 15
Immunogenicity of a Three-Dose Primary Series of mRNA COVID-19 Vaccines in Patients With Lymphoid MalignanciesAmy C Sherman, Nicolas C. Issa, Jennifer L. Crombie et al.|Open Forum Infectious Diseases|2022Cited by 10